Physician profile
Michael Dicaro
NPI 1184374639
$1,352.52
in general payments reported to CMS, 2019-2025
10 companies · $557 in 2025
The $557 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $650 · 2024: $146 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $382.04 | 2023-2025 | Hawkone, Ffrangio, Endurant Iis |
| Kestra Medical Technology Services, INC. | $247.83 | 2025 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $166.27 | 2024-2025 | Definity |
| Inari Medical, INC. | $123.61 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $123.55 | 2023 | |
| Viiv Healthcare Company | $122.06 | 2023 | Cabenuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.40 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $48.85 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $24.16 | 2024 | Inpefa |
| Chiesi USA, INC. | $15.75 | 2025 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dicaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.